ANSTO

27 January 2021
Inspection report details
Clipboard icon with checkbox
31 March 2020

On 27 March 2020, the CEO of ARPANSA, Dr Carl-Magnus Larsson, removed a licence condition from the ANSTO Nuclear Medicine (ANM) facility, allowing it to return to routine operation.

Clipboard icon with checkbox
6 December 2019

In June 2018, ARPANSA issued a direction to its licence holder, the Australian Nuclear Science and Technology Organisation (ANSTO), to initiate an independent review of its approach to occupational radiation safety at its nuclear medicine facility operated by ANSTO Health, now known as Health Products.

Clipboard
26 June 2019

On Friday 21 June 2019, ARPANSA was notified of a radiation contamination event at the Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine (ANM) production facility in Lucas Heights, New South Wales.

Clipboard icon with checkbox
27 May 2019

ARPANSA’s CEO, Dr Carl-Magnus Larsson has amended a licence issued to the Australian Nuclear Science and Technology Organisation (ANSTO) to operate the ANSTO Nuclear Medicine (ANM) facility.

Clipboard icon with checkbox
8 April 2019

ARPANSA has granted the Australian Nuclear Science and Technology Organisation (ANSTO) an amended license to allow for the limited production of molybdenum-99 in order to sustain supply.

Clipboard icon with checkbox
5 December 2018

On 4 December 2018, following a direction from ARPANSA’s CEO Dr Larsson, the Australian Nuclear Science and Technology Organisation (ANSTO) provided ARPANSA with an action plan that responds to 85

Clipboard icon with checkbox
22 October 2018

On 5 October 2018, following a direction from ARPANSA’s CEO Dr Carl-Magnus Larsson, the Australian Nuclear Science and Technology Organisation (ANSTO) provided ARPANSA with a report produced by an

Pages

Subscribe to RSS - ANSTO